Eosinophilic Asthma: Clinical Trials

5 completed. 5 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	5	Completed 5

Follow Eosinophilic Asthma: new trials by email Literature Review of Eosinophilic Asthma trials Research Report on Eosinophilic Asthma

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma	Phase 3	Completed	AstraZeneca	130	2025-03-28	2026-10-16
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Reslizumab, Placebo - Eosinophilic Asthma	Phase 3	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	511	2012-02-01	2016-06-27
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma	Phase 3	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	489	2011-04-01	2021-11-09
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma	Phase 3	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	464	2011-03-01	2021-11-09
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma	Phase 3	Completed	Teva Branded Pharmaceutical Products R&D, Inc.	315	2011-02-01	2016-06-06

Narrower conditions

Pulmonary Eosinophilia (5)

Broader conditions

Eosinophilia (5)  ·  Hematologic Diseases (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Hypereosinophilic Syndrome (5)  ·  Leukocyte Disorders (5)  ·  Lung Diseases (5)  ·  Respiratory Tract Diseases (5)

Interventions

Antibodies, Monoclonal, Humanized (4)  ·  reslizumab (4)  ·  benralizumab (1)

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc. (4)  ·  AstraZeneca (1)

Countries

United States (5)  ·  Canada (3)  ·  France (3)  ·  Argentina (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Colombia (2)  ·  Germany (2)  ·  Hungary (2)  ·  Israel (2)  ·  Mexico (2)  ·  Poland (2)  ·  Russia (2)  ·  Sweden (2)  ·  Australia (1)

Results publications

PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 27018175, PMID 27056586